Document Detail

Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada.
MedLine Citation:
PMID:  14523782     Owner:  NLM     Status:  MEDLINE    
Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS). We report common adverse events in 110 patients with suspected or probable SARS who were treated with ribavirin. Sixty-one percent of the patients had evidence of hemolytic anemia, and hypocalcemia and hypomagnesmia were reported in 58% and 46% of patients, respectively.
Sandra R Knowles; Elizabeth J Phillips; Linda Dresser; Larissa Matukas
Publication Detail:
Type:  Journal Article     Date:  2003-09-12
Journal Detail:
Title:  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America     Volume:  37     ISSN:  1537-6591     ISO Abbreviation:  Clin. Infect. Dis.     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-02     Completed Date:  2003-11-24     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9203213     Medline TA:  Clin Infect Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1139-42     Citation Subset:  IM    
Sunnybrook & Women's College Health Sciences Center, Toronto, Ontario, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Anemia, Hemolytic / etiology*
Antiviral Agents / adverse effects*,  therapeutic use
Canada / epidemiology
Disease Outbreaks
Hypocalcemia / etiology*
Middle Aged
Ribavirin / adverse effects*,  therapeutic use
Severe Acute Respiratory Syndrome / drug therapy,  epidemiology
Reg. No./Substance:
0/Antiviral Agents; 36791-04-5/Ribavirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Ophthalmological and biological features of the oculorespiratory syndrome after influenza vaccinatio...
Next Document:  Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2.